This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Glibutidum (Glibutidum)

GLIBUTID (Glibutidum).

Butylbiguanide hydrochloride.

Synonyms: Adebit, Silubin, Adebit, Buformin hydrochloride, Buformini hydrochloridum, Butylbiguanid, Butylnite, Gliporal, Glybigid hydrochloride, Krebon, Silubin, etc.

White crystalline powder of bitter taste. Easily soluble in water and alcohol.

It belongs to synthetic oral hypoglycemic (antidiabetic) drugs of the biguanide group.

The greatest hypoglycemic effect occurs 4 to 5 hours after taking the drug.

It is used to treat type II diabetes in adults. In combination with insulin, it is used for insulin-resistant forms of diabetes, as well as for resistance to antidiabetic drugs of sulfonylurea, for mild forms of diabetes accompanied by obesity, and for patients receiving insulin treatment for the labile course of diabetes.

Glibutide, like other biguanides (metformin, etc.), refers to oral antidiabetic drugs that cause a significant decrease in body weight in diabetic patients who are obese. These drugs reduce appetite, enhance anaerobic glycolysis, reduce the absorption of glucose from the gastrointestinal tract, and have an antilipid and fibrinolytic effect.

Assign inside with food. As an antidiabetic agent, take, starting with 0.1 g per day (50 mg in the morning and evening); depending on changes in blood and urine glucose, the dose can be gradually increased by 50 mg per day, but the daily dose should not exceed 300 mg.

Maintenance doses are usually 50-100 mg in the morning and 50 mg in the evening.

When combined with insulin, the dose of the latter is gradually reduced under the control of glucose in the blood and urine.

Together with sulfonylurea preparations, glibutide is prescribed in cases when the first cannot reduce hyperglycemia and glucosuria to the required level.

In the complex therapy of obesity, glibutide is usually taken at 0.1 g per day (often in combination with anorexigenic drugs).

Glibutide is well tolerated, but loss of appetite, nausea, vomiting, diarrhea, and a metallic taste in the mouth can be observed. At a later date from the start of treatment (after a month or more), weakness, weight loss are possible.

Side effects usually go away quickly with a dose reduction or drug withdrawal.

Contraindications to the use of glibutide are: absolute indications for the use of insulin, the absence of endogenous (or exogenously administered) insulin in the body, coma, acidosis, infectious diseases, albuminuria due to diabetic nephropathy, liver damage, diabetic angiopathy with the possibility of developing an inflammatory process, gangrene of limbs pregnancy.